200% shares Steyr Motors and PanGenomic Health! When will cancer-fighter BioNTech explode?

PanGenomic Health: 200% stock still looks cheap

What a performance: At the beginning of July, PanGenomic Health's stock was trading at EUR 0.40. Yesterday, it hit EUR 1.46. But the rally is likely only just beginning. With a market capitalization of just over CAD 30 million, significantly higher prices are likely possible. With the use of artificial intelligence, the Canadians aim to tap into the billion-dollar market for personalized alternative medicine and dietary supplements in North America. The Nara app is at the heart of the platform strategy. It is set to launch in the fourth quarter and will be supplemented with other offerings such as e-commerce.

The e-commerce platform agentahealth.ai, which is central to the Company's commercialization strategy, was already launched in August. With a personalized online shopping experience for alternative health products, the Company aims to offer consumers added value that they cannot currently find elsewhere. The goal is to provide users with tailored information about products that suit their individual health conditions, lifestyle, and personal goals. By connecting to the NaraCare.AI platform in the fourth quarter, Agenta Health will also provide evidence-based insights on product benefits, recommended dosages, and potential side effects - including interactions with other medications.

Following the release of the Nara app, PanGenomic will bring further innovations. For example, work is already underway on an RWE platform. This platform will collect data from clinical studies, traditional healing methods, and modern application practices and evaluate it using AI. The results will be made available not only to consumers but also to manufacturers, retailers, and researchers on a subscription basis. The launch is scheduled for the first quarter of 2026.

BioNTech: When will the stock react to its cancer advances?

While PanGenomic Health is in the midst of a price rally, BioNTech's share price has been fluctuating between EUR 80 and EUR 100 since March. This is surprising - especially in light of last week's news. The Mainz-based biotech company is making noticeable progress in the fight against cancer.

Last week, it announced two significant advances in its oncology pipeline, strengthening its position as a beacon of hope in cancer research. The antibody drug candidate BNT323 achieved its primary endpoint in a Phase 3 study in HER2-positive, inoperable, or metastatic breast cancer. In collaboration with Duality Biologics, the drug surpassed the efficacy of the established Roche drug Kadcyla. This brings potential approval closer and could see BioNTech enter the market for the first time with a cancer drug that could generate significant sales in the foreseeable future.

Just a few days later, the next positive news followed: Together with Bristol-Myers Squibb, BioNTech achieved promising results in a Phase 2 study of the immunotherapy candidate BNT327 ("pumitamig") in small cell lung cancer. More than three-quarters of patients responded to the treatment in combination with chemotherapy. The drug is already in Phase 3 development, marking an important step toward a possible market launch.

This put BioNTech fully on track to build a diversified oncology portfolio in the fight against cancer. While the data has been celebrated by experts, the stock has hardly reacted so far. This could lead to a massive jump in the share price if BioNTech successfully completes its ongoing studies, as billions in potential revenue would then be on the horizon.

Steyr: Tapping into a billion-dollar market in China

Like PanGenomic Health, the stock of Steyr Motors has more than tripled in the current year. While the market capitalization of over EUR 250 million compared to mid double-digit million revenues once seemed astonishing, the Austrians now appear to be rapidly growing into their valuation.

There were two pieces of strong news from China this week. On Monday, a joint venture with Shangyan Power Technology Jiangsu Co., Ltd. was announced. Under the agreement, Steyr Motors is guaranteed a minimum contribution of EUR 65 million in revenue and EUR 13 million in EBIT within five years. Shangyan Power is one of Asia's leading companies in the development and production of a wide range of diesel engines. The joint venture is intended to be a strategic milestone in Steyr's internationalization strategy. It opens up new growth opportunities in the ASEAN region and on a global level.

Yesterday, the next announcement followed: Just ten months after opening its office in Beijing, the specialist for customized engines for defense and civilian applications has received C2 certification for its marine engines. This is an important prerequisite for sales. With this certification, Steyr can address target markets ranging from commercial fleets and government customers to private recreational applications. The Austrians estimate the market volume in this area at around EUR 5 billion per year.

Steyr CEO Julian Cassutti commented: "China is the world's largest and most important market in shipbuilding. We see considerable market opportunities for our engine solutions and are very confident that we will be able to publish further positive updates in the near future in view of our order intake. Specifically, we see the opportunity to generate additional orders worth at least EUR 100 million for the period up to 2030, thanks to C2 certification. The associated expansion of the installed base of engines will also benefit the high-margin after-sales business, broadening the basis for future success."

PanGenomic shares still appear undervalued. E-commerce is set to become a significant source of revenue. To achieve this, the Canadians only need to secure a small share of the billion-dollar market. Steyr Motors is certainly not cheap at the moment. However, the Austrians are going full throttle operationally and could actually grow into their valuation faster than the market expects. If that happens, higher prices beckon. At BioNTech, the sideways movement could turn into a bang. Its substantial cash reserves provide solid downside protection for the stock.